Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Peripheral T-cell lymphoma: are all patients high risk?

Lauren Shea, Neha Mehta-Shah

Blood (2024) 144 (25): 2604–2612.

https://doi.org/10.1182/blood.2023020912

Published: 2024

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz

Blood (2024) 144 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2024-203577

Published: 2024

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Blood (2024) 144 (Supplement 1): 454.

https://doi.org/10.1182/blood-2024-206518

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

Imran A. Nizamuddin, Narendranath Epperla, Mary-Kate Malacek, Brad S. Kahl, Fei Wan, Anne Fischer, Chaz Moreno, Emily R. King, Anna Krivenko, Nancy L. Bartlett, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 985.

https://doi.org/10.1182/blood-2024-204521

Published: 2024

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Neha Mehta-Shah, Steven Horwitz, Pier Luigi Zinzani, Stefan K. Barta, Makoto Yamagishi, David M. Kurtz, Gensuke Takayama, Yoshiyuki Hizukuri, Weiguo Feng, Ken C. N. Chang, Takaya Moriyama, Keiko Nakajima, Ai Inoue, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 4342.

https://doi.org/10.1182/blood-2024-207594

Published: 2024

Journal Articles

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2024-211424

Published: 2024

Journal Articles

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

Imran A. Nizamuddin, Adeel Haq, Fei Wan, Marcus P. Watkins, Lauren Kelly Shea, Nancy L. Bartlett, Brad S. Kahl, Joyce Mhlanga, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 6334.

https://doi.org/10.1182/blood-2024-204458

Published: 2024

Journal Articles

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 4502.4.

https://doi.org/10.1182/blood-2024-209238

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Swaminathan P Iyer, Ranjit Nair, Neha Mehta-Shah, Don A. Stevens, Alessandra Tucci, Antonio Pinto, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4449.

https://doi.org/10.1182/blood-2024-209340

Published: 2024

Journal Articles

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Michael H. Kramer, Neha Mehta-Shah, Michael P. Rettig, Katherine Stricker, Melinda Harding, Feng Gao, Brett Ramsey, Peter Westervelt, Jan K Davidson-Moncada, Armin Ghobadi, John F. DiPersio, Geoffrey L. Uy

Blood (2024) 144 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2024-200809

Published: 2024

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

David A Russler-Germain, Fei Wan, Emily R. King, Chaz Moreno, Michelle Becker-Hapak, Patrick Pence, Joseph Rueve, Sushanth A Pureti, Dilan A. Patel, Brad S. Kahl, Neha Mehta-Shah, Todd A Fehniger, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2024-202085

Published: 2024

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Steven Horwitz, Salvia Jain, Jacob D. Soumerai, Michael T. Tees, Robert Stuver, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 467.

https://doi.org/10.1182/blood-2024-210482

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

NARROW

Peripheral T-cell lymphoma: are all patients high risk?

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only